## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.6% below STRENGTH zone (4.0-10.0%); PEG 1.62 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($230.11)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. ResMed (RMD): Evaluating the Stock’s Valuation After FDA Clearance for Its AI-Powered Smart Comfort CPAP Feature**
- Source: Sahm | 20251216T030950 | Bullish | Relevance: 100%
- ResMed (RMD) recently received FDA clearance for its AI-powered Smart Comfort CPAP feature, leading investors to evaluate its long-term growth prospects. The stock is currently trading at a modest discount to analyst targets despite consistent share price returns, suggesting potential undervaluation. Optimization strategies in manufacturing and logistics, combined with global scale, are expected to boost earnings and free cash flow.

**2. ResMed (NYSE:RMD) Downgraded to "Hold" Rating by Baird R W**
- Source: MarketBeat | 20251217T135046 | Somewhat-Bearish | Relevance: 100%
- Baird R W has downgraded ResMed (NYSE:RMD) from a "strong-buy" to a "hold" rating, despite the company recently beating quarterly earnings and revenue estimates. Analyst sentiment overall remains "Moderate Buy" with an average price target of $297.00. Insider selling activity has also been noted, with directors selling shares totaling over $1 million combined.

**3. 4,600 Shares in ResMed Inc. $RMD Purchased by Sanders Morris Harris LLC**
- Source: MarketBeat | 20251217T122421 | Somewhat-Bullish | Relevance: 100%
- Sanders Morris Harris LLC has acquired a new position in ResMed Inc. (NYSE:RMD), purchasing 4,600 shares valued at approximately $1.26 million. Other institutional investors have also increased their holdings, with analysts giving ResMed a "Moderate Buy" rating and an average target price of $297.00. The company recently exceeded quarterly EPS and revenue estimates, and declared a quarterly dividend of $0.60 per share.

**4. ResMed (RMD) Downgraded by Baird, Price Target Lowered to $275 | RMD Stock News**
- Source: GuruFocus | 20251216T122853 | Bearish | Relevance: 100%
- Baird has downgraded ResMed (RMD) from an Outperform rating to Neutral, lowering its price target from $300 to $275. This contrasts with recent analyst activities that maintained or raised ratings for the company. ResMed, a leading respiratory care device company, focuses on sleep apnea treatment and digital health initiatives.

**5. Baird downgrades ResMed stock rating to Neutral on slowing growth**
- Source: Investing.com | 20251216T100828 | Somewhat-Bearish | Relevance: 100%
- Baird downgraded ResMed (NYSE:RMD) from Outperform to Neutral, lowering its price target to $275.00 due to decelerating growth over the past three quarters. The firm noted slowing performance in ResMed’s U.S. masks and other category and expressed caution about increasing competition from private entities like React Health. Despite recent strong Q4 2025 earnings which exceeded forecasts, the downgrade reflects concerns about limiting multiple expansion and potential pricing concessions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Stifel | $260 | $270 | -4% |
| 2025-12-16 | Baird | $275 | $300 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Stifel | main | Hold |
| 2025-12-16 | Baird | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.0% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.0M in recent transactions.
3. Elevated short interest (8.2%): bears positioning against stock.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.62 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.4B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.62 |
| Forward P/E | 20.2 |
| Current P/E | 22.2 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.4% to -2.6% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.6pp (needs >4.0% for momentum thesis). AM_20 at -3.2% indicates price below own 20MA trend. Below SMA200 (0.96x), long-term trend not supportive. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.56% (CS: 18) | Weak |
| RSI_14 | 37.8 | Neutral |
| MACD Histogram | -0.40 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 0.951x | Below |
| vs SMA200 | 0.956x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $242.47
- **Stop Loss:** $230.11 (5.1% risk)
- **Target:** $254.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 76
- **Position Value:** $18,427.72
- **Portfolio %:** 18.43%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*